007370.KQ Jin Yang Pharmaceutical Co. Ltd

Healthcare Oil, Gas & Consumable Fuels KOSDAQ
3,405 KRW
Close of Oct 31, 2026
3,310 5,536
Market cap
KRW 48.1B
P/E
2.1x
P/B
0.30x
ROE
5.5%
Dividend yield
3.56%
Fundamental score
3.2/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 007370.KQ undervalued?

Graham number

The Graham number of Jin Yang Pharmaceutical Co. Ltd cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Jin Yang Pharmaceutical Co. Ltd fundamental analysis

15 of 22 checks passed

ROE 0/2

Low return on equity (5.5%), below 10%.

ROA 1/1

Return on assets (3.3%) is above the industry median (1.4%).

Profit Consistency 2/2

Profitable for 8 consecutive years.

Earnings Growth 5Y 1/1

Earnings per share grew over the past 5 years.

Earnings Acceleration 0/1

Last year's EPS growth (-39.3%) is not above the 5-year average (36.8% a year).

Earnings Growth vs Industry 0/1

Last year's EPS growth (-39.3%) is below the industry median (1.8%).

Revenue Growth 2/2

Revenue grew 16.5% a year over the past 3 years.

Short-term Liquidity 0/1

Current assets do not cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 0/2

Debt to equity cannot be calculated: debt is not reported or equity is negative.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Debt Coverage 0/1

Debt is not reported.

Interest Coverage 1/1

EBIT is 6.1x against interest expense, well covered.

PE vs Market 1/1

PE (2.1x) is below the market median (11.3x).

PE vs Industry 1/1

PE (2.1x) is below the industry median (11.4x).

PBV 1/1

Price to book (0.3x) is below the industry median (0.9x).

Graham Number 1/1

The price is below the Graham number (PE x PB = 0.6, limit 22.5).

PEG 1/1

PEG on 5-year earnings growth is 0.06, growth is cheap.

Dividend Yield 1/2

Dividend yield (3.6%) is above the bottom 25% of dividend payers in the market.

Dividend Stability 2/2

Dividends paid without a cut of more than 10% for 11 years.

Dividend Growth 1/1

Dividends paid grew over the past 5 years.

Payout Ratio 1/1

Payout ratio is 7.7%, covered by earnings.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Jin Yang Pharmaceutical Co. Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Jin Yang Pharmaceutical Co. Ltd

Jin Yang Pharmaceutical Co., Ltd. engages in the pharmaceutical business in South Korea. The company offers crivix tablets, Eszol tablets, atolan tablets, prescription drugs, and over-the-counter drugs. It also offers antilipidemic, antiplatelet, gastrointestinal, and respiratory agents; antithrombotics; NSAIDs; menopause symptoms treatment; and stomatological products. The company also exports its products. Jin Yang Pharmaceutical Co., Ltd. was founded in 1971 and is headqu…

Full company profile